宜坤行健生物医药

Yikun Xingjian is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the discovery and development of innovative small molecule drugs for oncology and immunology. The company's lead candidate, YK-001, is a potent and selective inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1), which is currently being evaluated in Phase 1 clinical trials for advanced solid tumors. By targeting HPK1, Yikun Xingjian aims to reverse T-cell exhaustion and enhance the body's natural anti-tumor immune response. The company's research strategy focuses on high-value, clinically validated pathways within the tumor microenvironment. Backed by investors like HighLight Capital, Yikun Xingjian is positioned to advance a pipeline of potential first-in-class therapies for patients with limited treatment options.